DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty

Abstract

Objective The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. Methods A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective knee or hip arthroplasty from 2007 to 2013. Propensity‐adjusted analyses examined whether infliximab stop timing (time between the most recent infusion and surgery) was associated with hospitalized infection within 30 days or prosthetic joint infection ( PJI ) within 1 year. Results Hospitalized infection within 30 days occurred after 270 of 4,288 surgeries (6.3%). Infliximab stop timing <4 weeks versus 8–12 weeks was not associated with an increase in infection within 30 days (propensity‐adjusted odds ratio [ OR ] 0.90 [95% confidence interval (95% CI ) 0.60–1.34]). The rate of PJI was 2.9 per 100 person‐years and was not increased in patients with stop timing <4 weeks versus 8–12 weeks (hazard ratio [ HR ] 0.98 [95% CI 0.52–1.87]). Glucocorticoid dosage >10 mg/day was associated with increased risk of 30‐day infection ( OR 2.11 [95% CI 1.30–3.40]) and PJI (more » HR 2.70 [95% CI 1.30–5.60]). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection. Conclusion Administering infliximab within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short‐ or long‐term serious infection compared to withholding infliximab for longer time periods. Glucocorticoid use, especially >10 mg/day, was associated with an increased infection risk.« less

Authors:
 [1];  [2];  [1];  [1];  [3];  [3];  [3];  [3]
  1. University of Pennsylvania Philadelphia
  2. University of Pennsylvania and Philadelphia Veterans Affairs Medical Center Philadelphia
  3. University of Alabama at Birmingham
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1407816
Resource Type:
Publisher's Accepted Manuscript
Journal Name:
Arthritis Care & Research
Additional Journal Information:
Journal Name: Arthritis Care & Research Journal Volume: 69 Journal Issue: 12; Journal ID: ISSN 2151-464X
Publisher:
Wiley Blackwell (John Wiley & Sons)
Country of Publication:
Country unknown/Code not available
Language:
English

Citation Formats

George, Michael D., Baker, Joshua F., Hsu, Jesse Yenchih, Wu, Qufei, Xie, Fenglong, Chen, Lang, Yun, Huifeng, and Curtis, Jeffrey R. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Country unknown/Code not available: N. p., 2017. Web. doi:10.1002/acr.23209.
George, Michael D., Baker, Joshua F., Hsu, Jesse Yenchih, Wu, Qufei, Xie, Fenglong, Chen, Lang, Yun, Huifeng, & Curtis, Jeffrey R. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Country unknown/Code not available. https://doi.org/10.1002/acr.23209
George, Michael D., Baker, Joshua F., Hsu, Jesse Yenchih, Wu, Qufei, Xie, Fenglong, Chen, Lang, Yun, Huifeng, and Curtis, Jeffrey R. Thu . "Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty". Country unknown/Code not available. https://doi.org/10.1002/acr.23209.
@article{osti_1407816,
title = {Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty},
author = {George, Michael D. and Baker, Joshua F. and Hsu, Jesse Yenchih and Wu, Qufei and Xie, Fenglong and Chen, Lang and Yun, Huifeng and Curtis, Jeffrey R.},
abstractNote = {Objective The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. Methods A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective knee or hip arthroplasty from 2007 to 2013. Propensity‐adjusted analyses examined whether infliximab stop timing (time between the most recent infusion and surgery) was associated with hospitalized infection within 30 days or prosthetic joint infection ( PJI ) within 1 year. Results Hospitalized infection within 30 days occurred after 270 of 4,288 surgeries (6.3%). Infliximab stop timing <4 weeks versus 8–12 weeks was not associated with an increase in infection within 30 days (propensity‐adjusted odds ratio [ OR ] 0.90 [95% confidence interval (95% CI ) 0.60–1.34]). The rate of PJI was 2.9 per 100 person‐years and was not increased in patients with stop timing <4 weeks versus 8–12 weeks (hazard ratio [ HR ] 0.98 [95% CI 0.52–1.87]). Glucocorticoid dosage >10 mg/day was associated with increased risk of 30‐day infection ( OR 2.11 [95% CI 1.30–3.40]) and PJI ( HR 2.70 [95% CI 1.30–5.60]). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection. Conclusion Administering infliximab within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short‐ or long‐term serious infection compared to withholding infliximab for longer time periods. Glucocorticoid use, especially >10 mg/day, was associated with an increased infection risk.},
doi = {10.1002/acr.23209},
journal = {Arthritis Care & Research},
number = 12,
volume = 69,
place = {Country unknown/Code not available},
year = {Thu Nov 02 00:00:00 EDT 2017},
month = {Thu Nov 02 00:00:00 EDT 2017}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1002/acr.23209

Citation Metrics:
Cited by: 42 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
journal, January 2007

  • Curtis, Jeffrey R.; Patkar, Nivedita; Xie, Aiyuan
  • Arthritis & Rheumatism, Vol. 56, Issue 4
  • DOI: 10.1002/art.22504

Generalized propensity score for estimating the average treatment effect of multiple treatments
journal, February 2011

  • Feng, Ping; Zhou, Xiao-Hua; Zou, Qing-Ming
  • Statistics in Medicine, Vol. 31, Issue 7
  • DOI: 10.1002/sim.4168

A tutorial on propensity score estimation for multiple treatments using generalized boosted models
journal, March 2013

  • McCaffrey, Daniel F.; Griffin, Beth Ann; Almirall, Daniel
  • Statistics in Medicine, Vol. 32, Issue 19
  • DOI: 10.1002/sim.5753

Infection Risk After Orthopedic Surgery in Patients With Inflammatory Rheumatic Diseases Treated With Immunosuppressive Drugs: Risk of Postoperative Infection in IRD Patients
journal, November 2013

  • Scherrer, Catrina B.; Mannion, Anne F.; Kyburz, Diego
  • Arthritis Care & Research, Vol. 65, Issue 12
  • DOI: 10.1002/acr.22077

A combined comorbidity score predicted mortality in elderly patients better than existing scores
journal, July 2011


The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study
journal, July 2016

  • Austin, Peter C.; Schuster, Tibor
  • Statistical Methods in Medical Research, Vol. 25, Issue 5
  • DOI: 10.1177/0962280213519716

Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty
journal, January 2013

  • Michaud, Kaleb; Fehringer, Edward V.; Garvin, Kevin
  • Arthritis Research & Therapy, Vol. 15, Issue 6
  • DOI: 10.1186/ar4385

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
journal, February 2011


Association Between Hospital and Surgeon Procedure Volume and the Outcomes of Total knee Replacement
journal, January 2004

  • Katz, Jeffrey N.; Barrett, Jane; Mahomed, Nizar N.
  • The Journal of Bone and Joint Surgery-American Volume, Vol. 86, Issue 9
  • DOI: 10.2106/00004623-200409000-00008

Epidemiology of Total Knee Replacement in the United States Medicare Population
journal, June 2005

  • Mahomed, Nizar N.
  • The Journal of Bone and Joint Surgery (American), Vol. 87, Issue 6
  • DOI: 10.2106/JBJS.D.02546

Constructing Inverse Probability Weights for Marginal Structural Models
journal, July 2008

  • Cole, S. R.; Hernan, M. A.
  • American Journal of Epidemiology, Vol. 168, Issue 6
  • DOI: 10.1093/aje/kwn164

Association Between Hospital and Surgeon Procedure Volume and Outcomes of Total Hip Replacement in the United States Medicare Population*
journal, January 2001


The Multiple Propensity Score as Control for Bias in the Comparison of More Than Two Treatment Arms: An Introduction From a Case Study in Mental Health
journal, January 2010


Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems: SAFETY OF BIOLOGIC TREATMENTS IN AUTOIMMUNITY
journal, September 2011

  • Herrinton, Lisa J.; Curtis, Jeffrey R.; Chen, Lang
  • Pharmacoepidemiology and Drug Safety, Vol. 20, Issue 11
  • DOI: 10.1002/pds.2196

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients
journal, August 2003


Validation of rheumatoid arthritis diagnoses in health care utilization data
journal, January 2011

  • Kim, Seo Young; Servi, Amber; Polinski, Jennifer M.
  • Arthritis Research & Therapy, Vol. 13, Issue 1
  • DOI: 10.1186/ar3260

Rates and Outcomes of Primary and Revision Total hip Replacement in the United States Medicare Population
journal, January 2003

  • Mahomed, Nizar N.; Barrett, Jane A.; Katz, Jeffrey N.
  • The Journal of Bone and Joint Surgery-American Volume, Vol. 85, Issue 1
  • DOI: 10.2106/00004623-200301000-00005

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
journal, June 2008

  • Saag, Kenneth G.; Teng, Gim Gee; Patkar, Nivedita M.
  • Arthritis & Rheumatism, Vol. 59, Issue 6
  • DOI: 10.1002/art.23721

Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009: OCCURRENCE OF PSORIASIS AND PSORIATIC ARTHRITIS
journal, May 2013

  • Asgari, Maryam M.; Wu, Jashin J.; Gelfand, Joel M.
  • Pharmacoepidemiology and Drug Safety, Vol. 22, Issue 8
  • DOI: 10.1002/pds.3447

Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis
journal, January 2009

  • Ferrante, M.; DʼHoore, A.; Vermeire, S.
  • Inflammatory Bowel Diseases, Vol. 15, Issue 7
  • DOI: 10.1002/ibd.20863

Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
journal, January 2010

  • Gilson, Mélanie; Gossec, Laure; Mariette, Xavier
  • Arthritis Research & Therapy, Vol. 12, Issue 4
  • DOI: 10.1186/ar3087

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
journal, September 2010


Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization
journal, November 2009

  • Liu, Liyan; Allison, James E.; Herrinton, Lisa J.
  • Pharmacoepidemiology and Drug Safety, Vol. 18, Issue 11
  • DOI: 10.1002/pds.1824

Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs’ administrative database study
journal, September 2014

  • Abou Zahr, Zaki; Spiegelman, Andrew; Cantu, Maria
  • Rheumatology International, Vol. 35, Issue 2
  • DOI: 10.1007/s00296-014-3121-0

Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis
journal, December 2008

  • Bongartz, Tim; Halligan, Christine S.; Osmon, Douglas R.
  • Arthritis & Rheumatism, Vol. 59, Issue 12
  • DOI: 10.1002/art.24060

Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized HealthCare Data, 1996 to 2009: Underrecognition in a US Health Care Setting
journal, December 2016

  • Curtis, Jeffrey R.; Harrold, Leslie R.; Asgari, Maryam M.
  • The Permanente Journal, Vol. 20, Issue 4
  • DOI: 10.7812/TPP/15-151

Prediction models of Medicare 90-day postdischarge deaths, readmissions, and costs in bowel operations
journal, March 2015


Rheumatoid arthritis: Perioperative management of biologics and DMARDs
journal, June 2015


Prosthetic Joint Infection Risk after TKA in the Medicare Population
journal, August 2009

  • Kurtz, Steven M.; Ong, Kevin L.; Lau, Edward
  • Clinical Orthopaedics and Related Research®, Vol. 468, Issue 1
  • DOI: 10.1007/s11999-009-1013-5

Patient-Related Risk Factors for Periprosthetic Joint Infection and Postoperative Mortality Following Total Hip Arthroplasty in Medicare Patients
journal, January 2012

  • Bozic, Kevin J.; Lau, Edmund; Kurtz, Steven
  • The Journal of Bone and Joint Surgery-American Volume, Vol. 94, Issue 9
  • DOI: 10.2106/JBJS.K.00072

Risk Factors for Infection Following Total Joint Arthroplasty in Rheumatoid Arthritis
journal, November 2013


Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
journal, January 2007

  • Schneeweiss, Sebastian; Setoguchi, Soko; Weinblatt, Michael E.
  • Arthritis & Rheumatism, Vol. 56, Issue 6
  • DOI: 10.1002/art.22600